Function-first antibody discovery
Open Access
- 1 August 2013
- journal article
- Published by Taylor & Francis in OncoImmunology
- Vol. 2 (8) , e25047
Abstract
Therapeutic antibodies may mediate antineoplastic effects by altering the biological functions of their target, by directly stimulating the demise of cancer cells or by activating antibody-dependent immune effector mechanisms. We have recently provided in vivo proof-of-concept for a “function-first” target and drug discovery platform in which antibodies against a multitude of tumor-associated antigens are screened for biological effects in a target-unbiased manner.Keywords
This publication has 10 references indexed in Scilit:
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T CellsCancer Immunology Research, 2013
- A Human ICAM-1 Antibody Isolated by a Function-First Approach Has Potent Macrophage-Dependent Antimyeloma Activity In VivoCancer Cell, 2013
- PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myelomaLeukemia, 2012
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignanciesBlood, 2011
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive ImmunityCancer Cell, 2010
- Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug–induced apoptosisBlood, 2009
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2008
- Rapid induction of apoptosis in B‐cell lymphoma by functionally isolated human antibodiesInternational Journal of Cancer, 2006
- Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagentsBlood, 2004
- Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targetsNature Medicine, 2000